FDA expedites review of experimental hepatitis C drug

Achillion Pharmaceuticals' hepatitis C drug candidate ACH-3102 received fast-track status from the FDA. The drug is undergoing a Phase I trial. CNBC/Reuters

Source: AABBsmartbrief